Trial Profile
International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Therapeutic Use
- Acronyms Monitor-GCSF
- Sponsors Sandoz
- 01 Jun 2019 Results published in the Supportive Care in Cancer
- 05 Jun 2018 Results assessing the safety and efficacy of biosimilar filgrastim in Breast Cancer patients from PIONEER (n=217) and MONITOR-GCSF (n=466) studies, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 06 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.